AC
AVBP icon

AXQ Capital’s ArriVent BioPharma AVBP Stock Holding History

AXQ Capital’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$222K Sell
6,392
-2,543
-28% -$75.1K 0.02% 697
2026
Q1 		$206K Buy
+8,935
New +$202K 0.03% 735
2025
Q3 		– Sell
-12,735
Closed -$277K – 868
2025
Q2 		$277K Buy
+12,735
New +$264K 0.09% 384

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AXQ Capital's AVBP Position: Q2 2026 in Review

AXQ Capital reduced its ArriVent BioPharma (AVBP) stake by 28% in Q2 2026, selling an estimated $75.1K and leaving 6,392 shares worth $222K. The position accounts for 0.02% of the portfolio, ranked #697.

AXQ Capital first reported a position in AVBP in Q2 2025 and has held it in 3 quarters since. The position peaked at $277K in Q2 2025. 158 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • AXQ Capital held 6,392 shares of ArriVent BioPharma worth $222K as of Q2 2026.
  • AXQ Capital sold 2,543 ArriVent BioPharma shares in Q2 2026, an estimated $75.1K.
  • ArriVent BioPharma made up 0.02% of AXQ Capital's portfolio in Q2 2026, its #697 holding.
  • AXQ Capital first reported a position in ArriVent BioPharma in Q2 2025 and has held it in 3 quarters since.
  • AXQ Capital's ArriVent BioPharma position peaked at $277K in Q2 2025.
  • 158 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on AXQ Capital's 13F filing for Q2 2026, filed 6 Aug 2026.